Glabellar Lines Clinical Trial
Official title:
Multicenter, Double-blind, Randomized, Parallel Design, Active-controlled Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of 100 Units of BMI 2006 and Botox® in Adult Patients in Need of Moderate or Severe Glabellar Lines
A multicenter, double-blind, randomized, parallel design, active control, phase 3 clinical trial to evaluate the efficacy and safety of 100 units of BMI 2006 and Botox® in adult patients in need of moderate or severe glabellar lines
Purpose of clinical trial: The purpose of this study was to evaluate the efficacy and safety of 20U dose administration of 100 units of BMI2006 in adult patients who needed moderate or severe glabellar lines. primary purpose Comparing the effectiveness after administration of each 20U dose of 'BMI2006 100 Units' or 'Botox® Week' for adult patients in need of moderate or severe glabellar lines, it was found that the BMI2006 injection group was non-inferior to the Botox® injection group. wanted to confirm. secondary purpose The purpose of this study was to evaluate the safety and effectiveness of 'BMI2006 100 Units' 20U compared to 'Botox® Injection' 20U for adult patients who need moderate or severe glabellar wrinkles. This clinical trial was designed as a multicenter, double-blind, randomized, parallel design, active-controlled Phase 3 clinical trial, and was intended for patients with moderate or severe glabellar lines. Only those subjects who have agreed in writing to voluntarily participate in the clinical trial and who are evaluated to meet the selection/exclusion criteria are 1:1 to the test group (BMI2006 week administration group) or control group (Botox®) in the order of participation in the clinical trial was randomly assigned. Subjects assigned with randomization numbers were intramuscularly injected (IM) with a total of 20U of clinical trial drugs in 5 places of 0.1 mL (4 U/0.1 mL) each on the glabellar line. Thereafter, at 4, 8, 12, and 16 weeks at intervals of 4 weeks, the institution was visited to evaluate the efficacy and safety for a total of 16 weeks. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04096326 -
AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines
|
Phase 2 | |
| Completed |
NCT02961673 -
The Safety and Efficacy Study of HU-014 Versus Botox® in Subject With Moderate to Severe Glabellar Lines
|
Phase 1/Phase 2 | |
| Completed |
NCT01271452 -
Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of Glabellar Lines
|
Phase 4 | |
| Completed |
NCT05013424 -
A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines
|
Phase 2 | |
| Completed |
NCT01189760 -
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
|
Phase 3 | |
| Completed |
NCT05100199 -
A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines
|
Phase 2 | |
| Completed |
NCT03721016 -
MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)
|
Phase 3 | |
| Completed |
NCT04157686 -
MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)
|
Phase 3 | |
| Completed |
NCT02353897 -
Patient and Physician's Satisfaction After a Long Term Treatment of Glabellar Lines With Dysport®
|
||
| Completed |
NCT03732833 -
MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines
|
Phase 3 | |
| Completed |
NCT06212960 -
Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines
|
Phase 1 | |
| Completed |
NCT05089357 -
Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin
|
||
| Completed |
NCT00408785 -
A Study Of BOTOX For The Treatment Of Glabellar Lines
|
Phase 3 | |
| Completed |
NCT05380154 -
Efficacy and Safety Assessment of Botulax® and BOTOX® for Improvement of Glabellar Lines.
|
Phase 3 | |
| Completed |
NCT01224015 -
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
|
Phase 3 | |
| Completed |
NCT05248880 -
A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar Lines
|
Phase 3 | |
| Completed |
NCT03216408 -
Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Moderate to Severe Glabellar Lines
|
Phase 3 | |
| Recruiting |
NCT06308198 -
A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar Lines
|
Phase 3 | |
| Completed |
NCT05298449 -
Phase 2 of HU-045 in Glabellar Lines
|
Phase 2 | |
| Not yet recruiting |
NCT06246552 -
Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines
|
Phase 2 |